The standard treatment for EGFR-positive lung cancer is an EGFR tyrosine kinase inhibitor (TKI), with one study showing a progression-free survival (PFS) of 18.9 months and overall survival (OS) of 38.6 months [3]. Here, EGFR is linked to lung carcinoma.